Generation of reactive T-cells thus could have been against another -likely minor- population of (myeloma) cells present at a site different from the one from which the random aspirate for molecular analysis was drawn (spatial heterogeneity [40]), or represent cross reactivity between antigens (as e.g. for MART1/HM1.24) [41]. The gene discussed is MLANA; the disease is plasma cell myeloma.